Global Access · International Regenerative Medicine Practice
BioCells Medical supports patients from across Europe, Central Asia, the Gulf region, and beyond. Every programme is built on the same clinical protocols, regardless of where the patient comes from.
Each programme is defined by the BioCells Medical clinical board on the basis of diagnosis, functional status, and safety considerations of the individual patient.
Programme Structure
Clinical Programme
•Physician oversight across every treatment day of the programme
•Neurology, immunology, and rehabilitation input on every protocol
•Full diagnostic and continuous patient monitoring infrastructure
•Follow-up and rehabilitation pathway integrated into every programme
•Clinical documentation shared with the patient's local physicians
International Patient Support
•Personal coordinator speaking the patient's language
•Visa invitation letter issued whenever required
•Accommodation and transfer logistics handled end-to-end
•Companion accommodation included at no additional cost
•Multilingual clinical communication — five languages in-house, more on request
•Continuity of care maintained after the programme ends
Who the Programme Is Built For
•Patients with ALS, advanced Parkinson's disease, MSA, or dementia
•Patients with progressive or primary progressive multiple sclerosis
•Adults with post-stroke sequelae or severe neuroinflammatory conditions
•Children with autism spectrum disorder or cerebral palsy
•Patients with rare autoimmune conditions and limited conventional options
•Families who require structured international access to regenerative care
Documented Cases
A selection of documented international patient cases from our clinical practice.
Medical Rationale
ALS is a progressive motor neuron disorder causing rapid neuromuscular degeneration, neuroinflammation, and loss of voluntary function. The objective was to support neuroprotective mechanisms and modulate neuroinflammatory activity in a patient with progressive motor decline.
Treatment Protocol
•Mesenchymal Stem Cell therapy (MSC) — neuroprotective and immunomodulatory support
•T-regulatory cell therapy — immune balance and neuroinflammation control
•Concentrated purified exosomes — intercellular signalling and tissue-support pathways
A dedicated rehabilitation specialist was assigned. Structured follow-up monitoring was initiated and clinical progress is being systematically documented.
Medical Rationale
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disorder affecting autonomic, cerebellar, and motor systems. Its complexity and rapid trajectory require personalised protocols delivered with precision and close medical oversight.
Treatment Protocol
•Allogeneic MSC infusion — systemic neuroprotective and anti-inflammatory effects
•MSC-derived exosomes — paracrine support for neurological pathways
•T-regulatory cell therapy — modulation of autoimmune components
•Personalised neuro-supportive protocol aligned with disease stage
Follow-Up
The patient remains under continued remote clinical monitoring, with protocol adjustments made in response to functional evolution.
Medical Rationale
Severe COPD with significant limitation of physical capacity and respiratory function. The clinical goal was to support pulmonary tissue regeneration and modulate chronic inflammation without imposing additional physiological stress on an already compromised respiratory system.
Treatment Protocol
•Autologous MSC infusion — pulmonary tissue support and anti-inflammatory activity
•Concentrated exosomes — regenerative biofactor delivery for pulmonary function
•Systemic intravenous administration over two consecutive days
•Full respiratory monitoring throughout the procedure
Follow-Up
Four-month follow-up documented meaningful improvements in exercise tolerance, oxygenation, and chronic cough reduction.
Medical Rationale
Cerebral palsy affecting motor development and functional independence. The protocol was designed around the child's developmental stage, with paediatric-adapted dosing and coordination with the family's existing physiotherapy plan.
Treatment Protocol
•Allogeneic MSC infusion — neuro-developmental support and neuroprotection
•MSC-derived exosomes — intercellular communication and regenerative signalling
•Rehabilitation integration — protocol coordinated with existing physiotherapy plan
•Two-day treatment delivery with paediatric-adapted clinical protocols
Follow-Up
Family-reported progress monitored remotely. Physiotherapy team provided updated notes for ongoing protocol optimisation.
Medical Rationale
Primary progressive MS with accumulating disability and limited response to available disease-modifying therapies. The protocol focused on immunomodulation and neuroprotection in a disease stage where conventional options are largely exhausted.
Treatment Protocol
•Allogeneic MSC infusion — immunomodulatory and neuroprotective approach
•MSC-derived exosomes — targeted molecular support for neurological pathways
•T-regulatory cell therapy — modulation of progressive neuroimmune dysfunction
•Personalised protocol adapted to PPMS disease stage and functional status
Follow-Up
Remote monitoring established. Protocol review scheduled at 3-month interval.
Medical Rationale
Progressive MS with sustained motor and cognitive decline. The patient had completed an initial treatment cycle; subsequent cycles were coordinated to maintain continuity of care and protocol progression.
•MSC-derived exosomes — continuation of previous regenerative programme
•Neurological status assessed pre- and post-treatment
•Protocol adjusted based on response to prior treatment cycle
Follow-Up
Continuing care pathway. Functional assessment conducted remotely 30 days post-treatment.
Medical Rationale
Autism spectrum disorder with significant behavioural dysregulation and sensory sensitivity. The protocol was designed with paediatric calibration and paced administration to minimise sensory disruption for the child.
Treatment Protocol
•Allogeneic MSC infusion — neuroimmune modulation and neuroplasticity support
•MSC-derived exosomes — neuroprotective and anti-neuroinflammatory signalling
•Paediatric-calibrated dosing and administration pace
•Coordination with the family's existing behavioural therapy team
Follow-Up
Family progress reports collected at 2, 6, and 12 weeks. Communication and behavioural markers tracked.
Medical Rationale
Chronic phase post-stroke sequelae with persisting motor and cognitive deficits. The clinical goal was to support neuroregeneration and vascular repair pathways in a patient with residual neurological impairment.
Treatment Protocol
•Autologous or allogeneic MSC infusion — neuroregeneration and vascular repair support
•MSC-derived exosomes — neuroprotective and anti-inflammatory molecular delivery
•Systemic intravenous administration with structured medical monitoring
•Neurofunctional support integrated with existing rehabilitation programme
Follow-Up
Physiotherapy and neurology teams notified. Remote progress review at 4 and 8 weeks.
Medical Rationale
Autism spectrum disorder in a paediatric patient with severe communication difficulties and environmental sensitivity. The protocol was built around a paediatric-calibrated approach with coordinated support from the child's local therapy team.
Treatment Protocol
•Allogeneic MSC infusion — neuroimmune regulation and neuroplasticity enhancement
•Concentrated exosomes — cell-free regenerative support for brain function
•Paediatric-adapted protocol — dosing, pace, and administration tailored to patient profile
•Coordination with local behavioural therapy team
Follow-Up
Family-reported outcomes collected at regular intervals. Coordination with local therapy providers maintained.
Medical Rationale
ALS with progressive motor neuron degeneration and advancing functional decline. The protocol focused on neuroprotection, inflammatory modulation, and neurotrophic support at an advanced disease stage.
Treatment Protocol
•Autologous MSC therapy — neuroprotection and neurotrophic factor support
•T-regulatory cell therapy — inflammatory modulation in the motor neuron environment
•Intrathecal or intravenous administration selected based on clinical evaluation
Follow-Up
Clinical monitoring ongoing. Family and attending physician provided structured follow-up data.
Medical Rationale
Relapsing MS with persistent residual disability following a recent relapse. The protocol was tailored to the relapsing disease trajectory, with emphasis on immune stabilisation and remyelination-supporting pathways.
•MSC-derived exosomes — biological support for remyelination pathways
•T-regulatory cell therapy — immune stabilisation in a relapsing disease context
•Monitoring protocol tailored to relapsing disease trajectory
Follow-Up
MRI and clinical evaluation scheduled at 3-month interval. Protocol continuity reviewed at follow-up.
Medical Rationale
Mid-stage Parkinson's disease with motor rigidity, gait instability, and emerging cognitive changes. The protocol focused on dopaminergic neuroprotection, paracrine signalling, and integrated rehabilitation support.
Treatment Protocol
•Allogeneic MSC infusion — dopaminergic neuroprotection and anti-inflammatory support
•MSC-derived exosomes — neuroregeneration and paracrine signalling
•Electro-Neuro Therapy (ENT) if clinically applicable — neurostimulation support
•Personalised rehabilitation plan coordinated with local physiotherapy provider
Follow-Up
Progress assessment conducted at 4 and 8 weeks. Family-reported functional changes documented.
International Patients
International Treatment Access
Patients from across Europe, Central Asia, the Gulf region, and beyond are part of the BioCells Medical programme — with personalised regenerative protocols and full international patient support.
